TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Valbiotis SA ( (FR:ALVAL) ) has shared an announcement.
Valbiotis has introduced Lipidrive, a scientifically proven alternative to red yeast rice for cholesterol management, in response to potential regulatory changes in Europe. With health authorities questioning the safety of red yeast rice, Valbiotis offers a compliant solution that aligns with future regulations, potentially impacting the dietary supplement market by providing a safe and effective option for maintaining normal cholesterol levels.
More about Valbiotis SA
Valbiotis is a French laboratory specializing in the design and distribution of scientifically validated dietary supplements aimed at preserving good health across all life stages. The company focuses on maintaining cardiometabolic health and well-being, addressing everyday health issues such as sleep, fatigue, mood management, immunity, and vitality. Founded in 2014 in La Rochelle, France, Valbiotis collaborates with leading academic centers and is recognized as an ‘Innovative Company’ by the BPI label.
YTD Price Performance: -23.62%
Average Trading Volume: 1,709
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €16.89M
For a thorough assessment of ALVAL stock, go to TipRanks’ Stock Analysis page.